Glenn Muir Net Worth

The estimated Net Worth of Glenn P Muir is at least $2.38 Milion dollars as of 5 September 2024. Mr. Muir owns over 25,000 units of G1 Therapeutics Inc stock worth over $2,066,402 and over the last 21 years he sold GTHX stock worth over $0. In addition, he makes $317,614 as Independent Director at G1 Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Muir GTHX stock SEC Form 4 insiders trading

Glenn has made over 72 trades of the G1 Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of GTHX stock worth $20,000 on 5 September 2024.

The largest trade he's ever made was exercising 196,000 units of G1 Therapeutics Inc stock on 5 May 2014 worth over $2,967,440. On average, Glenn trades about 16,280 units every 60 days since 2004. As of 5 September 2024 he still owns at least 289,818 units of G1 Therapeutics Inc stock.

You can see the complete history of Mr. Muir stock trades at the bottom of the page.

Glenn Muir biography

Glenn P. Muir serves as Independent Director of the Company. From September 2000 until his retirement in May 2014, Mr. Muir served as Executive Vice President, Finance and Administration of Hologic, Inc., or Hologic, a publicly traded manufacturer and supplier of medical products, and was Hologic’s Chief Financial Officer from 1992 until his May 2014 retirement. Mr. Muir served as the Controller of Hologic from October 1988 to 1992, including during its initial public offering in 1990. Mr. Muir served as a director of Hologic from 2001 through August 2013. Mr. Muir also has served as a member of the board of directors of a publicly traded life science company, Repligen Corporation, since September 2015, and a publicly held medical technology company, Neuronetics, Inc., since August 2017. From July 2014 until December 2017, Mr. Muir was a member of the board of directors of ReWalk Robotics Ltd., and from August 2014 until February 2017, Mr. Muir was a member of the board of directors of RainDance Technologies, Inc. Mr. Muir holds a B.B.A. with a major in accounting from the University of Massachusetts Amherst, an M.B.A. from the Harvard Graduate School of Business Administration and an M.Sc. in taxation from Bentley College Graduate School of Business. Mr. Muir is also a certified public accountant.

What is the salary of Glenn Muir?

As the Independent Director of G1 Therapeutics Inc, the total compensation of Glenn Muir at G1 Therapeutics Inc is $317,614. There are 15 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.

How old is Glenn Muir?

Glenn Muir is 61, he's been the Independent Director of G1 Therapeutics Inc since 2015. There are 6 older and 18 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.

What's Glenn Muir's mailing address?

Glenn's mailing address filed with the SEC is C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355.

Insiders trading at G1 Therapeutics Inc

Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman oraz Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.

What does G1 Therapeutics Inc do?

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Complete history of Mr. Muir stock trades at G1 Therapeutics Inc, Hologic, Repligen, Rewalk Robotics Ltd oraz Neuronetics Inc

G1 Therapeutics Inc executives and stock owners

G1 Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Avagliano,
  Chief Business Officer
• James Hanson,
  General Counsel, Secretary
• Mark Velleca,
  President, Chief Executive Officer, Director
• Terry Murdock,
  Chief Operating Officer
• Garry Nicholson,
  Independent Chairman of the Board
• Jennifer Moses,
  Chief Financial Officer
• Rajesh Malik,
  Chief Medical Officer, Senior Vice President - Research and Development
• Dr. Mark A. Velleca M.D., Ph.D.,
  Sr. Advisor & Director
• Mark Avagliano,
  Chief Bus. Officer
• Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
  Chief Medical Officer and Sr. VP of R&D
• Dr. Rajesh K. Malik,
  Chief Medical Officer and Sr. VP of R&D
• Andrew Perry,
  Chief Commercial Officer
• Jennifer K. Moses CPA,
  Chief Financial Officer
• Jennifer K. Moses,
  Chief Financial Officer
• Seth Rudnick,
  Independent Director
• Glenn Muir,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Fredric Eshelman,
  Independent Director
• Willie Deese,
  Independent Director
• Andrew Witty,
  Independent Director
• John Bailey,
  Independent Director
• Soma Gupta,
  Chief Commercial Officer
• Jay Strum,
  Chief Scientific Officer
• Terry L. Murdock,
  Chief Operating Officer
• Blake Jensen,
  VP of Quality & Compliance
• William C. Roberts,
  VP of Investor Relations & Corp. Communications
• Dr. Jay C. Strum,
  Chief Scientific Officer
• Alexander D. Smith M.S.,
  VP of Technical Operations
• John E. Bailey Jr.,
  CEO, Pres & Director
• Clay Hatteras Venture Advis...,
  
• Capital Management, L.P.Ra ...,
  
• Christy L Shaffer,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Ventures, Llc Eshelman,
  10% owner
• Clay Hatteras Venture Advis...,
  
• Barclay A Phillips,
  SVP & Chief Financial Officer
• Monica R. Thomas,
  Chief Legal & People Officer
• Jacks Lee,
  
• John Demaree,
  Chief Commercial Officer
• Alicia Secor,
  
• Cynthia Louise Flowers,
  
• Andrew Perry,
  Chief Commercial Officer
• Norman Sharpless,
  
• John W. V Umstead,
  Chief Financial Officer